ACRS ▼ -4.0% - Aclaris Therapeutics, Inc.
$ACRS - Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4R? Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma
27-OCT-2026 06:00 AM ET
Share this post
More filings for $ACRS
ACRS ▼ -3.4% - Aclaris Therapeutics, Inc.Oct 27, 2026ACRS - Aclaris Therapeutics, Inc. - SEC Filing Update (21-SEP-2026) | ThinkSabio - Stocks SimplifiedSep 21, 2026
View full $ACRS filing history →💬 Comments
Loading comments…
Leave a comment